The DNPH1 Knockout PaTu 8988t Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal population in which the DNPH1 gene has been disrupted in the human pancreatic ductal adenocarcinoma cell line PaTu 8988t. This heterogeneous knockout pool serves as a loss-of-function model for investigating DNPH1-dependent nucleotide metabolism and genomic stability pathways, preserving genetic heterogeneity akin to tumor tissues.
The PaTu 8988t cell line is an epithelial model derived from a liver metastasis of human pancreatic adenocarcinoma. It is a well-established system for examining molecular mechanisms of pancreatic cancer progression, metastatic behavior, and chemoresistance. The cell’s metastatic origin and frequent c-Myc dysregulation make it particularly relevant for studying how nucleotide salvage pathways contribute to pancreatic cancer cell fitness.
DNPH1 encodes a hydrolase that dephosphorylates 2′-deoxynucleoside 5′-monophosphates, thereby diminishing cellular dNTP pools and influencing DNA replication accuracy. As a direct transcriptional target of c-Myc, DNPH1 operates downstream of c-Myc signaling, and its overexpression can deplete dNTPs, altering the balance maintained by ribonucleotide reductase for DNA polymerases. This disruption fosters replication stress and DNA damage, detectable by markers like ??-H2AX.
In the context of PaTu 8988t cells, DNPH1 knockout provides an opportunity to dissect the intersection between c-Myc-driven oncogenesis, nucleotide metabolism, and genomic instability. Pancreatic adenocarcinoma cells frequently harbor elevated c-Myc activity and imbalanced dNTP pools, and the loss of DNPH1 allows researchers to evaluate consequences on cell proliferation, cell cycle distribution, and sensitivity to nucleoside analog drugs. This model also permits investigation of replication stress responses and potential synthetic lethal interactions in a metastatic background.
Typical applications include western blotting and RT-qPCR for confirming DNPH1 ablation, dNTP pool quantification via enzymatic or mass spectrometry methods, and cell viability assays to assess proliferation and drug responsiveness. DNA damage can be monitored through ??-H2AX immunofluorescence or immunoblotting, while flow cytometry facilitates cell cycle and apoptosis analysis. Screening for altered sensitivity to nucleoside analogs such as gemcitabine or cytarabine is especially valuable. For more information or to place an order, please contact Ascent Research.
